التفاصيل البيبلوغرافية
| العنوان: |
Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification |
| المؤلفون: |
Hironao Okubo, Hitoshi Ando, Shunsuke Nakamura, Yusuke Takasaki, Koichi Ito, Yuka Fukuo, Kenichi Ikejima, Hiroyuki Isayama |
| المصدر: |
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024) |
| بيانات النشر: |
Wiley, 2024. |
| سنة النشر: |
2024 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
aldolase, cabozantinib, dose modification, hepatocellular carcinoma, muscle injury, relative dose intensity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Abstract Aim To investigate the outcomes of cabozantinib in patients with unresectable hepatocellular carcinoma (uHCC), focusing on dose setting and modification. Methods We retrospectively analyzed 34 Japanese patients who received cabozantinib for uHCC. Trough concentrations (Ctrough) of cabozantinib were also measured weekly for 6 weeks in the 18 patients. Results Sixteen patients received ≥40 mg (high‐dose group), and 18 patients received 20 mg (low‐dose group). Dose escalations were performed in 27.8% of the patients in the low‐dose group. Although median duration of the first dose reduction or interruption in the low‐dose group was twice that in the high‐dose group (28 vs. 14 days, p |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2045-7634 |
| Relation: |
https://doaj.org/toc/2045-7634 |
| DOI: |
10.1002/cam4.70222 |
| URL الوصول: |
https://doaj.org/article/bd189ccd8e1748df98a3f1cc1ca5db23 |
| رقم الانضمام: |
edsdoj.bd189ccd8e1748df98a3f1cc1ca5db23 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder